Piper Sandler analyst Edward Tenthoff assumedcoverage of Biomea Fusion (BMEA) with an Overweight rating and $7 price target The company is developing icovamenib to treat diabetes, a covalent menin inhibitor, the analyst tells investors in a research note. Piper views Biomea as an emerging diabetes and obesity play.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: